A Caesars Republic hotel is coming to California's Wine Country
Developed in partnership with the Dry Creek Rancheria Band of Pomo Indians, the project will completely transform the existing resort, which overlooks vineyards and the Russian River. Caesars did not say when the transformation would be completed.
Plans call for a 100-room hotel with a spa, pool and fitness center, as well as a casino floor with more than 1,000 slot machines and 28 table games. The resort will be home to a variety of food and beverage venues, including a steakhouse, an upscale café, an Asian concept, a sports bar and a wine bar featuring an outdoor deck with valley views.
The resort will be part of the Caesars Rewards loyalty program, joining the company's portfolio of 50-plus properties globally.
The expansion news follows the recent opening of a Caesars Republic hotel in Lake Tahoe, Nevada. The lifestyle brand debuted its first property, the Caesars Republic Scottsdale, in Arizona last year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
CHO Plus Enters into Project Agreement with BARDA's BioMaP Consortium to Develop High Productivity Cell Lines for Filovirus Monoclonal Antibody Production
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) for up to $10.4 million for developing high productivity Chinese hamster ovary cell lines for manufacturing filovirus monoclonal antibodies for therapeutic use over a 30-month period. The agreement has a base period and two option periods. Lawrence Forman, Founder and CEO of CHO Plus, said, 'We are very pleased to receive this project agreement award from BARDA which involves using our engineered cell lines to produce monoclonal antibodies against highly contagious and lethal filoviruses.' In addition to cell line development, CHO Plus will be partnering with privately held Avid Bioservices of Tustin, CA to scale up the monoclonal antibodies production for eventual industrial scale requirements. Nick Green, CEO of Avid Bioservices said, 'We are thrilled CHO Plus selected Avid Bioservices to be their scale up partner to deliver these important monoclonal antibodies to support BARDA's strategic initiative for biodefense. The Avid team looks forward to our collaboration.' This project has been funded in whole or in part with Federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority, under OT number #75A50123D00003. About CHO Plus, Plus was founded in 2014 to address the high costs and capacity issues facing therapeutic protein manufacturers. We have developed cutting-edge technologies for creating high productivity GMP-compliant mammalian cell lines to be used for the manufacture of therapeutic proteins and, more recently, viral vectors for gene therapy. About Avid BioservicesA dedicated commercial biologics CDMO focused on the development and CGMP manufacture of biopharmaceuticals. Avid Bioservices is in Orange County, CA. Employing over 350 team members, with approximately 213,000 ft2 of space spanning two campuses. This includes a mammalian protein process development facility, two mammalian protein commercial manufacturing facilities, an early phase center of excellence facility, and corporate offices. Visit Avid Bioservices at and to learn more. About BARDAThe Biomedical Advanced Research and Development Authority (BARDA) within the U.S Department of Health and Human Services' (HHS) Administration for Strategic Preparedness and Response (ASPR) is responsible for the advanced research, development, and procurement of medical countermeasures, for chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases. About Biopharmaceutical Manufacturing Preparedness Consortium The Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) supports BARDA and is comprised of industry partners across the drug and vaccine manufacturing supply chain, including manufacturers of required raw materials and consumables, developers of innovative manufacturing technologies, and suppliers of fill finish services. The consortium seeks to expand the industrial and manufacturing base for medical countermeasures to include the requisite capabilities, flexibilities, and strategies to secure needed medical supplies to prepare the United States for future health security threats. Visit to learn more and follow @BioMaP-Consortium on LinkedIn. ContactLawrence FormanFounder and CEO, CHO Plus, Plus, Inc.: while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
6 minutes ago
- Yahoo
Are Wall Street Analysts Predicting Super Micro Computer Stock Will Climb or Sink?
San Jose, California-based Super Micro Computer, Inc. (SMCI) develops and manufactures advanced server and storage solutions built on a modular and open architecture. Valued at $33.8 billion by market cap, the company offers servers, storage systems, motherboards, full racks, chassis, and accessories worldwide. Shares of this AI server giant have underperformed the broader market over the past year. SMCI has declined 6.8% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 18.4%. However, in 2025, SMCI stock is up 91%, surpassing SPX's 7.6% rise on a YTD basis. More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Narrowing the focus, SMCI's underperformance is also apparent compared to the Technology Select Sector SPDR Fund (XLK). The exchange-traded fund has gained about 28.1% over the past year. However, SMCI's robust gains on a YTD basis outshine the ETF's 12.8% returns over the same time frame. SMCI has been underperforming due to tariffs and delayed customer-platform decisions. The company is facing challenges, including customers evaluating next-generation AI platforms and experiencing margin contraction due to price competition. SMCI also had a one-time inventory write-down on older-generation components. Competition from Hewlett Packard Enterprise Company (HPE) and Dell Technologies Inc. (DELL) in the infrastructure-as-a-service space adds further pressure on SMCI. On May 6, SMCI shares closed up more than 2% after the company reported its Q3 results. Its adjusted EPS declined 53% year over year to $0.31. The company's revenue totaled $4.6 billion, representing a 19.5% year-over-year increase. SMCI expects full-year revenue in the range of $21.8 billion to $22.6 billion. For the current fiscal year, ended in June, analysts expect SMCI's EPS to decline 14.4% to $1.72 on a diluted basis. The company's earnings surprise history is disappointing. It missed the consensus estimates in two of the last three quarters while beating the forecast on another occasion. Among the 16 analysts covering SMCI stock, the consensus is a 'Hold.' That's based on four 'Strong Buy' ratings, three 'Moderate Buys,' six 'Holds,' one recommends a 'Moderate Sell,' and two advocate a 'Strong Sell.' This configuration is less bearish than a month ago, with no analyst suggesting a 'Moderate Sell.' On Jul. 31, Samik Chatterjee from JPMorgan Chase & Co. (JPM) maintained a 'Hold' rating on SMCI with a price target of $46. While SMCI currently trades above its mean price target of $43, the Street-high price target of $70 suggests a 20.2% upside potential. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Verge
9 minutes ago
- The Verge
Microsoft's Windows XP Crocs are no joke
Microsoft isn't done celebrating its 50th anniversary just yet. Multiple employees tell me that Microsoft has created limited edition Windows XP-themed Crocs. They even come with a Clippy shoe charm if the Bliss wallpaper on your feet wasn't enough 50-year nostalgia. The anniversary edition Crocs are currently available for preorder for Microsoft employees, who 'get first dibs' ahead of a 'worldwide launch,' I'm told. The $80 pair of Crocs include a six-pack of Microsoft Jibbitz that you can attach to your shoes, with nostalgic options like the original MSN logo, the Internet Explorer icon, Clippy, and a mouse pointer. On top the Crocs feature the iconic blue sky and clouds from the Windows XP wallpaper, with a green sole to mimic the grass. The photograph of the rolling hills and blue skies of California was initially a stock photo before Microsoft acquired the rights and used it as the default wallpaper for millions of Windows XP users. It could be the most viewed photograph in the world, making it an instantly recognizable image for many. You'll also get a Bliss drawstring backpack to wear, just in case onlookers were unclear if your footwear was the Windows XP wallpaper or not. Hopefully each pair won't smell like a dusty beige PC and Internet Explorer doesn't automatically install once you're wearing them. I asked Microsoft about its Windows XP Crocs, but the company refused to comment. I'm expecting to see an official announcement in the coming days. Posts from this author will be added to your daily email digest and your homepage feed. See All by Tom Warren Posts from this topic will be added to your daily email digest and your homepage feed. See All Exclusive Posts from this topic will be added to your daily email digest and your homepage feed. See All Features Posts from this topic will be added to your daily email digest and your homepage feed. See All Microsoft Posts from this topic will be added to your daily email digest and your homepage feed. See All Report Posts from this topic will be added to your daily email digest and your homepage feed. See All Tech
